StockpollyBeta
Get App
Popularity #3,863
OKUR · NASDAQ · Biotechnology

OnKure Therapeutics (OKUR)

Develops mutation-selective PI3Kα medicines for cancer and vascular anomalies.

$2.95
vs last close−0.16 (−5.00%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
21−211014534171616141517
Research & development14−7911137131312111213
7−14144−4444344
General & administrative0−14140−4444344
Other expenses000000000000
Operating income−2121−10−14−5−34−17−16−16−14−16−17
1−3001−1111102
Interest income000000111102
Interest expense000000000000
Other non-operating income−1300−1−2−1−1−1−10−2
Income before tax−1919−10−14−4−35−16−15−15−14−15−15
Net income from continuing operations−1919−10−14−4−35−16−15−15−14−15−15
Net income−1919−10−14−4−35−16−15−15−14−15−15
EPS, basic−$1.44$1.39−$0.71−$1.06−$0.28−$2.64−$1.19−$1.14−$1.09−$0.99−$1.11−$0.31
EPS, diluted−$1.44$1.39−$0.71−$1.06−$0.28−$2.64−$1.19−$1.14−$1.09−$0.99−$1.11−$0.31
Weighted average shares, basic131313131313131414141450
Weighted average shares, diluted131313131313131414141450
EBITDA−1919−9−14−4−31−16−15−14−13−15−15
Depreciation & amortization000001000000
EBIT−1919−10−14−4−32−16−15−15−13−15−15